Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 4, 2025, and June 5, 2025, surrounding the Company's 2025 Annual Meeting of Stockholders. The filing details corporate governance changes, executive departures, and shareholder-approved amendments to the Company's capital structure and equity incentive plans.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and structural changes.
Material Changes and Corporate Actions
- Board Appointment: Jill Broadfoot was appointed to the Board of Directors, the Audit Committee (as Chair), and the Corporate Governance and Nominating Committee. She received an option to purchase 48,800 shares of common stock, vesting over three years.
- Executive Departure: Kerri-Ann Millar resigned as Chief Financial Officer, effective June 13, 2025. CEO Daniel R. Passeri will serve as interim principal financial and accounting officer.
- Capital Stock Amendment: Stockholders approved an amendment to increase authorized capital stock from 210,000,000 to 310,000,000 shares and authorized common stock from 200,000,000 to 300,000,000 shares.
- Stock Incentive Plan: Stockholders approved the 2025 Stock Incentive Plan.
Shareholder Voting Results
| Proposal | For | Against | Abstain |
|---|---|---|---|
| Amendment to Increase Authorized Shares | 29,484,310 | 7,611,547 | 117,824 |
| Ratification of Auditor (RSM US LLP) | 31,122,850 | 1,027,154 | 5,063,677 |
| Advisory Vote on Executive Compensation | 13,186,558 | 2,634,667 | 138,967 |
| 2025 Stock Incentive Plan | 13,849,249 | 2,007,505 | 103,438 |
Note: Significant broker non-votes (21,253,489) were recorded for director elections and the advisory compensation vote.
Outlook, Risks, and Contingencies
The Company has entered into a standard indemnification agreement with the new director, Ms. Broadfoot, which may require the Company to indemnify her for certain expenses, judgments, and penalties arising from her service. The interim appointment of the CEO as CFO introduces a temporary leadership transition in financial oversight until a permanent replacement is designated.
Key Facts for Investor Verification
- Verify the timeline for the recruitment and appointment of a permanent Chief Financial Officer to replace Kerri-Ann Millar.
- Review the full text of the 2025 Stock Incentive Plan (Exhibit 99.1) to understand dilution potential and grant terms.
- Monitor the impact of the increased authorized share count on future capital raising activities.
- Assess the implications of the significant number of broker non-votes on director elections and executive compensation.